Pegascy Biotech has acquired istiratumab, a HER3/IGF-1R #bispecific #antibody pioneering rare #pediatric #cancer. KOL Birgit Geoerger Gustave Roussy is the PI of this trial in patients with recurrent Ewing #sarcoma, an aggressive #disease and still an unmet #medical need

Pegascy Biotech is investigating recurrent #endometrial #cancer using HER3/IGF-1R #bispecific #antibody istiratumab. KOL Alexandra Leary Gustave Roussy is the PI of this phase II #Clinicaltrial on a #gyneacological #disease with increasing worldwide incidence and unmet #medical needs

A bispecific to double target an orphan disease#ewing#massard#tabernero#delattre

Pegascy Biotech successfully obtained the famous #deeptech label from BPI (Public Investment Bank) for a cutting-edge project using an anti-HER3/IGF-1R bispecific #antibody in #clinicaltrials on 2 neglected recurrent #diseases: #pediatric Ewing #sarcoma and endometrial #cancer

science.org/doi/10.1126/sc…

cancer.gov/news-events/ca…

Don't miss this game-changing paper from Birgit Geoerger in CANCER DISCOVERY demonstrating that molecular profiling provides benefits for #children with selected key drivers at #cancer #relapse. Great advances for pediatric trials. Gustave Roussy Fabrice Barlesi pubmed.ncbi.nlm.nih.gov/35292802/

Mismatch repair deficiency has been studied in the context of endometrial #cancer treatment options in this work led by Dr Leary Gustave Roussy. Beside chemo and immuno, bispecificAb could emerge as new therapies soon Benjamin Besse FabriceAndre Fabrice Barlesi pubmed.ncbi.nlm.nih.gov/36521352/

Proud to be selected by #PSCC as high potential project in #cancer #therapeutics! This validates our strategy driven by scientific rationale and led by a team of talented oncologists and biologists. We are committed to bring innovation to the #patients ! parissaclaycancercluster.org/en/postulez